Free Newsletter
Shire recalls ADHD drug patches
Drug patches have had a tough time lately, with recalls coming on everything from too-tight adhesive to slits in active-ingredient reservoirs. Today, the recalled patch in the news is Shire's Daytrana, an attention deficit hyperactivity disorder med. Two lots were withdrawn on concerns about the patch's liner, which could be difficult for patients to remove before applying the patch. Shire recalled a limited number of patches for the same reason just a year ago.
Shire sells the patches on license from Noven Pharmaceuticals, which sent out a statement saying that it has identified the "definitive root cause" of the defect and is now "aggressively testing potential solutions."
- read the Associated Press article
Related Articles:
Another company recalls fentanyl patch
Mylan steps into pain-patch void
AHA: Kids need EKG before ADHD meds
FDA approves Lilly's ADHD drug Strattera
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





